Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-κB in chronic hepatitis C

Liver International

Volumn 28, Issue 3, 2008, Pages 339-346

  Hung, Chao Hung ^a   Lee, Chuan Mo ^a   Kuo, Fang Ying ^a   Jiang, Shu Rong ^a   Hu, Tsung Hui ^a   Chen, Chien Hung ^a   Wang, Jing Houng ^a   Lu, Sheng Nan ^a   Eng, Hock Liew ^a   Changchien, Chi Sin ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Fas; Fibrosis; Hepatitis C virus; Nuclear factor B; Steatosis; Tumour necrosis factor

Indexed keywords

CASPASE 3; DEATH RECEPTOR; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL DAMAGE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; TRANSCRIPTION INITIATION;

ADULT; ANTIGENS, CD95; CASPASE 3; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; UP-REGULATION;

EID: 39549090862     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01676.x     Document Type: Article

References (35)

1. Poynard T, Bedossa P, Oplon P, for the OBSTIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Nature history of liver fibrous progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
2. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
3. Poynard T, Ratziu V, Charlotte F, Goodman Z, Mchutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
4. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36(Suppl. 1): S47-56.
5. Lee CM, Lu SN, Hung CH, et al. Hepatitis C virus genotypes in southern Taiwan: Prevalence and clinical Implications. Trans R Soc Trop Med Hyg 2006; 100: 767-74.
6. Hung CH, Chen CH, Lee CM, et al. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. J Viral Hepat 2008; 15: 58-65.
7. Tong MJ, El-Farra NS, Reijes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
8. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000; 32: 91-6.
9. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16.
10. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepaitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27: 1717-22.
11. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.
12. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
13. Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
14. Hu KQ, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: A retrospective study on a large cohort of patients in the United States. J Hepatol 2004; 40: 147-54.
15. Hung CH, Kuo FY, Wang JH, et al. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther 2006; 11: 483-9.
16. Clouston AD, Jonsson JR, Purdie DM, et al. Steatosis and chronic hepatitis C: Analysis of fibrosis and stellate cell activation. J Hepatol 2001; 34: 314-20.
17. Walsh MJ, Vanags DM, Clouston AD, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: A mechanism for increased liver injury. Hepatology 2004; 39: 1230-8.
18. Seidel N, Volkmann X, Länger F, et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 2005; 42: 113-20.
19. Kurose I, Higuchi H, Miura S, et al. Oxidative stress-mediated apoptosis of hepatocytes exposed to acute ethanol intoxication. Hepatology 1997; 25: 368-78.
20. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001; 34: 248-53.
21. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-43.
22. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-17.
23. Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
24. Tai DI, Tsai SL, Chen YM, et al. Activation of nuclear factor kappaB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000; 31: 656-64.
25. Mann EA, Stanford S, Sherman KE. Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kappaB activation. Virus Res 2006; 121: 51-7.
26. Dela Peña A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005; 129: 1663-74.
27. Boya P, Larrea E, Sola I, et al. Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: Decreased RelA expression is associated with enhanced fibrosis progression. Hepatology 2001; 34: 1041-8.
28. Luedde T, Trautwein C. Intracellular survival pathways in the liver. Liver Int 2006; 26: 1163-74.
29. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
30. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
31. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.
32. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004; 11: 455-8.
33. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: Genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007; 46: 999-1008.
34. Chen G, Goeddel DV. TNF-R1 signaling: A beautiful pathway. Science 2002; 296: 1634-5.
35. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999; 284: 321-5.